Advances in the pharmacotherapeutic management of refractory peptic ulcers
Resumen: Introduction: Refractory peptic ulcer is now a rare disease since most peptic ulcers heal with appropriate treatment with proton pump inhibitors (PPIs) and/or Helicobacter pylori eradication. Areas covered: The most frequent cause of apparent refractoriness is lack of adherence to treatment. Persistence of H. pylori infection, use or abuse (often surreptitious) of high dose non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin (ASA) are the two major causes of true refractory ulcers. There is a growing number of peptic ulcers which are not linked to either NSAIDs or H. pylori infection. Refractoriness in these ulcers can be linked to gastric acid hypersecretion, rapid PPI metabolization, ischemia, chemo-radiotherapy, immune diseases, more rarely to other drugs or be fully idiopathic. Treatment of the cause of the ulcer, if known, is essential. This review is based on pertinent publications retrieved by a selective search in PubMed, with particular attention to refractory peptic ulcer. Expert opinion: High-dose PPI or the new potassium competitive acid blocker or the combination of PPIs with misoprostol can be recommended in these cases. Other more experimental treatments such the topical application of platelet-rich plasma or mesenchymal stem cells have also been suggested. Surgery is the last option, but there is no guarantee of success, especially in NSAID or ASA abusers.
Idioma: Inglés
DOI: 10.1080/14656566.2023.2199922
Año: 2023
Publicado en: EXPERT OPINION ON PHARMACOTHERAPY 24, 7 (2023), 825-833
ISSN: 1465-6566

Factor impacto JCR: 2.5 (2023)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 180 / 354 = 0.508 (2023) - Q3 - T2
Factor impacto CITESCORE: 5.6 - Pharmacology (medical) (Q2) - Pharmacology (Q2)

Factor impacto SCIMAGO: 0.687 - Medicine (miscellaneous) (Q2) - Pharmacology (medical) (Q2) - Pharmacology (Q2)

Tipo y forma: Revisión (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.


Exportado de SIDERAL (2024-11-22-12:04:34)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Medicina



 Registro creado el 2024-01-23, última modificación el 2024-11-25


Postprint:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)